- Co announced one-year data from its landmark SYNTAX trial comparing percutaneous coronary intervention using the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System to contemporary coronary artery bypass graft surgery. The overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction.
- The Co. made the announcement at the annual European Society of Cardiology meeting in Munich, Germany.
- The results announced today showed comparable safety for the two treatment groups, with a combined rate of all-cause death, stroke and MI of 7.6% for PCI and 7.7% for CABG (p=0.98). The rate of stroke itself was 0.6% for PCI as compared to 2.2% for CABG (p=0.003). Overall 12- month MACCE was significantly higher for PCI (17.8% compared to 12.1% for CABG, p=0.0015).

Other headlines for [BSX]

• BSX Yesterday 04:55pm
  Boston Scientific Corp Co-founders have reported more margin calls- Peter Nicholas sold 2.5M shares.
  
• BSX 11/25/2008 04:13pm
  Boston Scientific Corp Co-founder has sold 3.86M shares (less than 1% of outstanding) due to margin calls - filing dated 11/21- Back on 11/19, the co-founder sold $4M of stock and on 10/31, the executive sold 60K more...
  
• BSX 11/19/2008 04:24pm
  Boston Scientific Corp Co-founder has sold $4M of stock - filing- Back on 10/31, the official was forced to sell 60K shares and on 10/29 he sold $29.2M of stock. - Both prior sales were due to margin calls. - As of more...
  
• BSX 11/19/2008 04:20pm
  Boston Scientific Corp UBS Initiates BSX with Buy
  
• BSX 11/10/2008 08:30am
  Boston Scientific Corp FDA approves Apex PTCA Dilatation Catheter- The Apex Catheter represents the next generation of dilatation catheter technology, utilizing a new Bi-Segment inner shaft for improved pushability and more...
  

Healthcare sector headlines

• MAKO Today 07:46am
  MAKO Surgical Receives FDA Clearance to Market Both Its Version 2.0 Tactile Guidance System and Its Bicompartmental Knee Resurfacing Implant System- Announced it received two 510(k) clearances from the US FDA to more...
  
• UNH Today 07:40am
  UnitedHealth Group Inc Guides 2009 Commercial Enrollment down 1-1.5M y/y; Full year decline of 450-800K commercial risk based members- Sees 2009 Medicare advantage enrollemnt up 10-135K y/y - Sees 2009 Medicade more...
  
• MYL Today 07:30am
  Mylan Laboratories Inc Announces settlement agreement with Novartis related to Femara First-to-File Opportunity- Under the agreement, Mylan is provided a patent license that will enable the company to market Letrozole more...
  
• XNPT Today 07:30am
  XenoPort Inc Reports Results from a Phase 2 Clinical Trial of XP19986 as a Treatment for the Symptoms of Gastroesophageal Reflux Disease- The primary analysis comparing XP19986 to placebo did not reach more...
  
• TGEN Today 07:30am
  Targeted Genetics Corp Realigns product development priorities; Implements cost reduction measures- To focus on its ocular and neurological product candidates and its first use of expressed RNAi - Company has reduced its more...